Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1161/01.str.5.5.643 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Higher Rate of Reinterventions After Transfemoral Carotid Artery Stenting in Symptomatic Patients: A Retrospective Stroke Center's Cohort Study between 2015-2024.
Ann Vasc Surg
January 2025
Division of Vascular and Endovascular Surgery, Mayo Clinic, Jacksonville, FL. Electronic address:
Introduction: Carotid artery stenosis is a significant contributor to ischemic strokes, and its surgical management includes carotid artery endarterectomy (CEA), transfemoral carotid artery stenting (TF-CAS), and trans carotid artery revascularization (TCAR). CEA has traditionally been preferred, but TF-CAS and TCAR are also excellent alternative options if the anatomy of the vessels allows them. This study reports our short- and mid-term outcomes after carotid artery revascularization in symptomatic patients at a stroke center.
View Article and Find Full Text PDFCarotid artery atherosclerotic stenosis is an important annual cause of stroke in the United States. Moreover, the incidence of carotid artery stenosis is significantly increasing due to the widespread popularity of high fat and high salt diets, sedentary lifestyles, and the increasing age of the population. Of major importance to cardiovascular specialists is the fact that individuals with atherosclerotic carotid artery stenosis can have a prevalence of atherosclerotic coronary artery disease as high as 50 to 75%.
View Article and Find Full Text PDFInvestigation of treatment delay in a complex healthcare process using physician insurance claims data: an application to symptomatic carotid artery stenosis.
BMC Health Serv Res
November 2024
School of Population and Public Health, University of British Columbia, Vancouver, Canada.
Article Synopsis
- Delays in healthcare processes can lead to serious health issues, highlighting the need for better understanding of current processes through flowcharts generated from real-world data.
- This study analyzed physician insurance claims and hospital data for patients who had carotid endarterectomy, aiming to find the reasons behind treatment delays between 2008 and 2014.
- Results showed that each patient experienced unique treatment timelines, and while some medical activities were beneficial, others, like unnecessary follow-ups, contributed to delays in surgery, with the flowchart from the data being difficult to interpret.
Neuro-ophthalmic outcomes after carotid intervention for ocular symptoms.
J Vasc Surg
November 2024
Department of Vascular and Endovascular Surgery, Mayo Clinic Health System, Eau Claire, WI. Electronic address:
Background: The long-term neuro-ophthalmic outcomes after carotid intervention in patients presenting with preoperative visual symptoms vary widely based on the underlying etiology of retinal ischemia and are not well understood.
Methods: We performed a retrospective review of consecutive patients presenting with retinal ischemia who subsequently underwent carotid intervention from January 2018 to December 2022. Patients were classified into three groups (group I: amaurosis fugax/vascular transient monocular vision loss, group II: ocular ischemic syndrome [OIS], and group III: central/branch retinal artery occlusion).
Ginkgo biloba extract safety: Insights from a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events.
J Ethnopharmacol
January 2025
Faculty of Integrated Traditional Chinese and Western Medicine, Hebei University of Chinese Medicine, Shijiazhuang, 050200, China; Institute of Traditional Chinese Medicine, Chengde Medical University / Hebei Province Key Research Office of Traditional Chinese Medicine Against Dementia / Hebei Province Key Laboratory of Traditional Chinese Medicine Research and Development / Hebei Key Laboratory of Nerve Injury and Repair, Chengde, 067000, China. Electronic address:
Ethnopharmacological Relevance: A traditional Chinese medicine extracted from the Ginkgophyta, Ginkgo biloba is commonly used to treat cardiac cerebral disease all over the world. Limited data exist regarding adverse drug reactions associated with Ginkgo biloba extract post-marketing.
Aim Of The Study: Currently, the drug safety profile of Ginkgo biloba extract is assessed using a substantial volume of case safety reports within the FDA Adverse Event Reporting System (FAERS) database.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!